[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352960-105":59,"doc-detail-352960-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","immunoscore-and-beyond-evolution-and-clinical-integration-of-immune-contexture-based-biomarkers-across-solid-tumours","Immunoscore and beyond: evolution and clinical integration of immune contexture-based biomarkers across solid tumours","","Tumour immune microenvironmental features increasingly shape cancer progression, prognosis, and therapeutic response, challenging the adequacy of anatomy-based TNM staging. Immunoscore (IS), first validated in colorectal cancer, provides spatial assessment of CD3+ and CD8+ T cells in tumour core and invasive margin. The review synthesizes evidence from adapted IS models, computational and imaging surrogates across multiple solid tumours, highlighting translational promise and methodological heterogeneity. High IS scores often associate with improved survival and refined risk stratification, but inter-study variability, limited external validation, and context dependence constrain comparability. Harmonisation, prospective validation, and integration with genomic and imaging biomarkers are needed for clinical implementation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunoscore-and-beyond-evolution-and-clinical-integration-of-immune-contexture-based-biomarkers-across-solid-tumours/352960/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunoscore-and-beyond-evolution-and-clinical-integration-of-immune-contexture-based-biomarkers-across-solid-tumours/352960.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-09","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the Immunoscore aim to address compared with TNM staging?","Question",{"text":113,"@type":114},"TNM staging summarizes tumour burden and metastasis, but it does not account for effects of the host immune response. Immunoscore targets spatial features of anti-tumour immunity within the tumour microenvironment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which immune cells and regions does Immunoscore evaluate?",{"text":118,"@type":114},"Immunoscore assesses CD3+ and CD8+ T cells in two spatial compartments: the tumour core and the invasive margin.",{"name":120,"@type":111,"acceptedAnswer":121},"Why do results across studies remain difficult to compare and reproduce?",{"text":122,"@type":114},"The review emphasizes inter-study variability, limits from retrospective and single-centre designs, limited external validation, and potential overfitting in computational models, along with biological context dependency.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352960,1790296471,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Review  \nPUBLISHED 08 May 2026  \nDOI 10.3389/fimmu.2026.1832715  \nOPEN ACCESS  \nEDITED BY  \nSophia N. Karagiannis,  \nKing’s College London, United Kingdom  \nREVIEWED BY  \nJyothi Thyagabhavan Mony, Agilent Technologies, United States Nemanja Maletin,  \nUniversity of Novi Sad, Serbia  \n*CORRESPONDENCE  \nEsteban Orenes-Piñero  \neorenes@um. es  \nRECEIVED 17 March 2026  \nREVISED 09 April 2026  \nACCEPTED 15 April 2026  \nPUBLISHED 08 May 2026  \nCITATION  \nOrenes-Piñero E, Ros-Martnez S, Alonso-Romero JL and Ortega  \nGarca JA (2026) Immunoscore and beyond: evolution and clinical integration of immune contexture-based biomarkers across solid tumours.  \nFront. Immunol. 17:1832715 .  \ndoi: 10.3389/fimmu.2026.1832715  \nCOPYRIGHT  \n© 2026 Orenes-Piñero, Ros-Martnez, Alonso-Romero and Ortega-Garca. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nImmunoscore and beyond: evolution and clinical integration of immune contexture-based biomarkers across solid tumours  \nEsteban Orenes-Piñero 1,2*, Silverio Ros-Mart ´ınez 3,  \nJos´e Luis Alonso-Romero 3 and Juan Antonio Ortega-Garc ´ıa 4  \n1 Department of Biochemistry and Molecular Biology, University of Murcia, Murcia, Spain, 2 Proteomic Unit, Instituto Murciano de Investigaciones Biosanitarias (IMIB) Pascual Parrilla, Murcia, Spain,  \n3 Department of Oncology, Hospital Clnico Universitario Virgen de la Arrixaca (HCUVA), Murcia, Spain,  \n4 Paediatric Environmental Health Specialty Unit, Hospital Clnico Universitario Virgen de la Arrixaca (HCUVA), Murcia, Spain  \nThe tumour immune microenvironment is increasingly recognised as a critical determinant of cancer progression, prognosis, and therapeutic response, challenging the sufﬁciency of anatomy-based staging systems such as TNM. The Immunoscore (IS), originally validated in colorectal cancer, provides a standardised, spatially resolved assessment of CD3+ and CD8+ T cells within the tumour core (TC) and invasive margin (IM) . Expanding upon this framework, adapted and modiﬁed IS models, as well as computational and imaging-based surrogates, have been investigated across multiple solid malignancies, including non-small-cell lung cancer, hepatocellular carcinoma, head and neck cancers, gastric cancer, melanoma, and bladder cancer. This review synthesises the current evidence, emphasising both the translational potential and methodological heterogeneity of IS-based approaches. High IS or adapted scores generally correlate with improved survival and may reﬁne risk stratiﬁcation, complementing conventional TNM staging. However, inter-study variability limits comparability and reproducibility. Retrospective designs, single-centre cohorts, limited external validation, and potential overﬁtting in computational models further constrain the strength of evidence. Biological context dependency, immune-exclusion phenotypes, and the dynamic evolution of the tumour immune landscape complicate interpretation, underscoring that high immune cell density does not universally equate to effective antitumour immunity. Overall, the IS and related immunecontexture classiﬁers constitute a biologically grounded framework that bridges tumour immunology and clinical oncology. While promising, widespread clinical implementation requires methodological harmonisation, prospective validation, and integration with genomic, systemic, and imaging biomarkers. By highlighting both achievements and current limitations, this review provides a balanced perspective on the potential and challenges of translating immune contexturebased metrics into precision oncology.  \nKEYWORDS  \nbladder ","cbCaiiypvTI4uiIz","https://ap.wps.com/l/cbCaiiypvTI4uiIz","pdf",677020,14,"English","# Highlights\n# 1 Introduction\n## Tumour staging and the role of host immunity","[{\"question\":\"What problem does the Immunoscore aim to address compared with TNM staging?\",\"answer\":\"TNM staging summarizes tumour burden and metastasis, but it does not account for effects of the host immune response. Immunoscore targets spatial features of anti-tumour immunity within the tumour microenvironment.\"},{\"question\":\"Which immune cells and regions does Immunoscore evaluate?\",\"answer\":\"Immunoscore assesses CD3+ and CD8+ T cells in two spatial compartments: the tumour core and the invasive margin.\"},{\"question\":\"Why do results across studies remain difficult to compare and reproduce?\",\"answer\":\"The review emphasizes inter-study variability, limits from retrospective and single-centre designs, limited external validation, and potential overfitting in computational models, along with biological context dependency.\"}]","Immunoscore and beyond: evolution and clinical integration of immune contexture-based biomarkers across solid tumours | PDF",1790102318,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5230f5a82d160a62d2bd427e8a746137.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3159bc12361b5531d9edf9e4abe6d62c.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f409a6832a866bc69e438e60742aee3.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7653b2c3fad7204e1a7e9f91c320fc2.webp",980,1385]